NIKKEI 225
38,855.37 -44.65 (-0.11%) HANG SENG
18,821.16 -6.19 (-0.03%) CRUDE OIL
79.95 +2.23 (+2.87%) GOLD FUTURES
2,354.00 +19.50 (+0.84%) DOW
38,737.34 -332.25 (-0.85%) Bitcoin GBP
52,808.80 -2,078.35 (-3.79%)
MRK Sep 2024 120.000 call
- Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
- Simply Wall St.
Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...
- Business Wire
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
RAHWAY, N.J., May 28, 2024--Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer
